New Stent-Graft aims to fix aneurysms without cutting off blood flow

NCT ID NCT07005141

Recruiting now Disease control Sponsor: Archo Medical S.A Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This early trial tests a new device called the iHub stent-graft in 10 adults with iliac artery aneurysms. The device is placed through a small incision to seal off the aneurysm while keeping blood flowing to the internal iliac artery. Researchers will check for serious problems within the first month and monitor how well the device works over a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iHub endovascular iliac branch stent-graft system
What this could lead to: If it works, this could offer a safer, less invasive way to treat iliac aneurysms while keeping blood flow to the internal iliac artery.
What could go wrong: This is a very small early study with only 10 participants, so results may not apply to everyone. The device could fail, cause leaks, or block blood vessels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC ANEURYSM, ABDOMINAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal aortic aneurysm Iliac Aneurysm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC ANEURYSM, ABDOMINAL ILIAC ANEURYSM

Contacts and locations

Locations

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP
RECRUITING

São Paulo, São Paulo, 05403-000, Brazil
Instituto de Ensino e Pesquisa Dr. Irineu May Brodbeck - Hospital Baía Sul S/A
RECRUITING

Florianópolis, Santa Catarina, 88020210, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.